Clinical Trials: Country-Specific Clinical Trials

FDA Bioresearch Monitoring (BIMO) Inspections in U.S. Clinical Trials: What Sponsors Should Expect

Posted on digi By digi

Sponsors and investigators should: (1) maintain inspection readiness at all times; (2) implement comprehensive SOPs; (3) train staff on GCP and FDA expectations; (4) conduct internal audits and mock inspections; (5) establish robust CAPA systems; (6) document oversight of CROs and vendors; (7) validate electronic systems for Part 11 compliance; (8) ensure timely adverse event reporting; (9) maintain accurate delegation and training logs; and (10) engage compliance officers in inspection preparation.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

UK Clinical Trial Transparency Requirements

Posted on digi By digi

Transparency requirements apply differently across trial types:

Oncology: High public interest requires rapid disclosure of results.
Pediatrics: Lay summaries must be tailored to parents and guardians.
Rare Diseases: Data sharing is vital to advance knowledge in small populations.
Decentralized Trials: Transparency obligations include disclosure of digital endpoints and remote data collection methods.

Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials

EU Clinical Trials Information System (CTIS) Explained

Posted on digi By digi

Sponsors conducting multinational trials must align document versions and manage translations carefully for Part II submissions. Also, legal representatives are required for non-EU sponsors to access CTIS and conduct regulatory interactions. Ethics Committees still operate under national law, but their assessments are logged within the CTIS framework.
Click to read the full article.

Clinical Trials in EU, Country-Specific Clinical Trials

GCP Inspections by DCGI: Common Findings

Posted on digi By digi

GCP inspections in India are governed by the New Drugs and Clinical Trials Rules (NDCTR), 2019, which empower CDSCO to conduct audits and inspections of clinical trial sites, sponsors, and ethics committees. These inspections are carried out to verify GCP compliance, review documentation, ensure protection of trial participants, and validate reported trial data.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

IND Safety Reporting Requirements in U.S. Clinical Trials

Posted on digi By digi

Sponsors should: (1) implement robust pharmacovigilance systems; (2) establish clear SOPs for SUSAR reporting; (3) train investigators and staff; (4) use independent DMCs; (5) harmonize global reporting rules; (6) validate electronic reporting systems; (7) monitor vendor compliance; (8) maintain real-time safety databases; (9) audit safety processes; and (10) conduct periodic CAPA reviews.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Impact of Brexit on UK Clinical Trials Regulation

Posted on digi By digi

Brexit has unique implications across different trial categories:

Oncology: Large-scale oncology trials must now manage dual submissions to EU and UK regulators.
Rare Diseases: Small populations require cross-border collaboration, complicated by separate EU and UK requirements.
Decentralized Trials: MHRA has been proactive in adopting digital and remote methodologies, diverging from some EU approaches.
Pediatrics: Sponsors must meet independent UK ethics review processes in addition to EU Pediatric Investigation Plans (PIPs).

Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials

Role of ICMR Guidelines in Indian Clinical Research

Posted on digi By digi

The ICMR, under the Department of Health Research, Ministry of Health and Family Welfare, is India’s apex body for formulating ethical guidelines in biomedical research. The ICMR guidelines are recognized by national regulators such as CDSCO and institutional ECs across India. These guidelines are revised periodically to incorporate global ethical standards, technological advancements, and socio-cultural realities.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

GDPR and Clinical Trial Data Management in the EU

Posted on digi By digi

While GDPR is directly applicable across the EU, individual Member States can have additional rules on the use of personal data for health research. For example, France requires specific approvals from CNIL, while Germany’s states may impose layered requirements. Sponsors conducting multi-country trials must assess local data protection nuances.
Click to read the full article.

Clinical Trials in EU, Country-Specific Clinical Trials

Clinical Trial Insurance and Liability Coverage in the United States

Posted on digi By digi

Sponsors should: (1) maintain robust subject injury coverage; (2) include indemnification clauses in CTAs; (3) harmonize insurance across states and sites; (4) engage IRBs early for subject injury statement approval; (5) verify investigator malpractice policies; (6) ensure CROs maintain adequate insurance; (7) review policies annually; (8) align coverage with global trial requirements; and (9) train site staff on how to explain subject injury protections to participants.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Role of HRA in Ethics Review for UK Trials

Posted on digi By digi

The HRA tailors ethics oversight for specific trial categories:

Pediatrics: Consent must involve both parents and age-appropriate assent forms for children.
Oncology: RECs scrutinize use of placebo and crossover designs to ensure ethical acceptability.
Rare Diseases: Ethics reviews focus on balancing risk in small patient populations with unmet medical needs.
Decentralized Trials: HRA has introduced guidance on eConsent and remote monitoring to support ethical standards in digital trials.

Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials